| Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality E Gogola, AA Duarte, JR de Ruiter, WW Wiegant, JA Schmid, R de Bruijn, ... Cancer cell 33 (6), 1078-1093. e12, 2018 | 280 | 2018 |
| Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts XY Woo, J Giordano, A Srivastava, ZM Zhao, MW Lloyd, R de Bruijn, ... Nature genetics 53 (1), 86-99, 2021 | 157 | 2021 |
| Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer S Annunziato, JR de Ruiter, L Henneman, CS Brambillasca, C Lutz, ... Nature communications 10 (1), 397, 2019 | 75 | 2019 |
| Truncated FGFR2 is a clinically actionable oncogene in multiple cancers D Zingg, J Bhin, J Yemelyanenko, SM Kas, F Rolfs, C Lutz, JK Lee, ... Nature 608 (7923), 609-617, 2022 | 55 | 2022 |
| MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling D Zimmerli, CS Brambillasca, F Talens, J Bhin, R Linstra, L Romanens, ... Nature communications 13 (1), 6579, 2022 | 49 | 2022 |
| TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development LM Cornelissen, AP Drenth, E Van Der Burg, R De Bruijn, CEJ Pritchard, ... Genes & development 34 (3-4), 179-193, 2020 | 48 | 2020 |
| Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality E Gogola, AA Duarte, JR de Ruiter, WW Wiegant, JA Schmid, R de Bruijn, ... Cancer Cell 35 (6), 950-952, 2019 | 38 | 2019 |
| CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer JM Houthuijzen, R De Bruijn, E Van Der Burg, AP Drenth, E Wientjens, ... Nature Communications 14 (1), 183, 2023 | 33 | 2023 |
| Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays P Bouwman, I van der Heijden, H van der Gulden, R de Bruijn, ... Clinical Cancer Research 26 (17), 4559-4568, 2020 | 26 | 2020 |
| Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1-versus BRCA2-deficient mammary tumors J Bhin, MP Dias, E Gogola, F Rolfs, SR Piersma, R de Bruijn, JR de Ruiter, ... Cell reports 42 (5), 2023 | 16 | 2023 |
| Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers P Ter Brugge, SC Moser, I Bièche, P Kristel, S Ibadioune, A Eeckhoutte, ... Nature Communications 14 (1), 1958, 2023 | 16 | 2023 |
| Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system S Klarenbeek, CW Doornebal, SM Kas, N Bonzanni, J Bhin, ... Oncoimmunology 9 (1), 1724049, 2020 | 13 | 2020 |
| Epithelial-to-mesenchymal transition drives invasiveness of breast cancer brain metastases AS Margarido, R Uceda-Castro, K Hahn, R de Bruijn, L Kester, I Hofland, ... Cancers 14 (13), 3115, 2022 | 12 | 2022 |
| Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer L Ratz, C Brambillasca, L Bartke, MA Huetzen, J Goergens, O Leidecker, ... Breast Cancer Research 24 (1), 41, 2022 | 11 | 2022 |
| A BRCA1 coiled-coil domain variant disrupting PALB2 interaction promotes the development of mammary tumors and confers a targetable defect in homologous recombination repair EM Pulver, C Mukherjee, G van de Kamp, SJ Roobol, MB Rother, ... Cancer research 81 (24), 6171-6182, 2021 | 11 | 2021 |
| A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression SJ Hutten, R de Bruijn, C Lutz, M Badoux, T Eijkman, X Chao, M Ciwinska, ... Cancer cell 41 (5), 986-1002. e9, 2023 | 8 | 2023 |
| Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice LM Cornelissen, L Henneman, AP Drenth, E Schut, R de Bruijn, ... Journal of Mammary Gland Biology and Neoplasia 24, 305-321, 2019 | 8 | 2019 |
| MYC promotes immune-suppression in TNBC via inhibition of IFN signaling D Zimmerli, CS Brambillasca, F Talens, J Bhin, A Bhattacharya, ... bioRxiv, 2021.02. 24.432659, 2021 | 6 | 2021 |
| Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts XY Woo, J Giordano, A Srivastava, ZM Zhao, MW Lloyd, R de Bruijn, ... Nature genetics 53 (5), 761-761, 2021 | 5 | 2021 |
| GATA3 truncating mutations promote cistromic re-programming in vitro, but not mammary tumor formation in mice LM Cornelissen, R de Bruijn, L Henneman, Y Kim, W Zwart, J Jonkers Journal of Mammary Gland Biology and Neoplasia 24 (3), 271-284, 2019 | 3 | 2019 |